Viridian Therapeutics Inc

NASDAQ:VRDNUnited States

Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Contact Information

Headquarters

221 CRESCENT STREET, SUITE 103AWALTHAM, MA, United States 02453

Phone

617-272-4600

Fax

302-655-5049

Executives

Independent Chairman of the Board

Tomas Kiselak

President, Chief Executive Officer, Director (Principal Executive Officer)

Stephen Mahoney

Chief Operating Officer

Thomas Beetham

Senior Vice President - Finance and Accounting (Principal Financial Officer and Principal Accounting Officer)

Seth Harmon

Chief Medical Officer

Thomas Ciulla